初始良性前列腺穿刺活检后的标准化前列腺癌发病率和死亡率
该基于人群的分析比较了1995至2016年丹麦37231例初始经直肠超声引导系统穿刺活检为非恶性男性的后续前列腺癌发病与死亡风险与年龄和日历年匹配的丹麦人群。校正后标准化发病比为5.2(95%CI 5.1-5.4),标准化死亡比为0.74(95%CI 0.67-0.81),各年龄组间差异有统计学意义(P<0.001),年轻男性中发病比和死亡比更高。
要点
- 初始经直肠超声系统穿刺活检为非恶性的男性,前列腺癌发病率远高于匹配人群(SIR 5.2,95%CI 5.1-5.4)。
- 该人群前列腺癌死亡风险低于人群平均水平(SMR 0.74,95%CI 0.67-0.81)。
- 作者认为初始穿刺漏诊癌症的肿瘤学风险低,增加初始活检敏感性的尝试不合理,当前随访可能过度积极。
核心结论
- 初始经直肠超声系统穿刺活检为非恶性的男性前列腺癌发病率远高于年龄和日历年匹配人群,但前列腺癌死亡风险低于人群平均水平。
- 作者认为初始穿刺漏诊癌症的肿瘤学风险低,增加初始活检敏感性的尝试不合理,当前对非恶性活检后的随访可能过度积极,尤其是60岁以上男性。
研究设计与样本
- 基于人群的分析,比较1995至2016年丹麦所有初始经直肠超声系统穿刺活检为非恶性的男性队列(N=37231)与来自NORDCAN 9.1数据库按年龄和日历年匹配的丹麦人群。
- 计算年龄和日历年校正的标准化前列腺癌发病比(SIR)和前列腺癌特异性死亡比(SMR),并用Cochran Q检验评估年龄组间异质性。
主要发现
- 删失中位时间为11年,4434例男性随访超过15年。
- 校正后SIR为5.2(95%CI 5.1-5.4),校正后SMR为0.74(95%CI 0.67-0.81)。
- 各年龄组间SIR和SMR估计值均有差异(两者P<0.001),年轻男性中SIR和SMR更高。
关键数值与推荐
- 校正后标准化前列腺癌发病比(SIR)5.2(95%CI 5.1-5.4)。
- 校正后前列腺癌特异性死亡比(SMR)0.74(95%CI 0.67-0.81)。
- 年龄组间异质性检验SIR和SMR均为P<0.001。
临床怎么用
- 作者认为初始穿刺漏诊癌症的肿瘤学风险低,增加初始活检敏感性的尝试不合理。
- 作者认为当前非恶性活检后的随访可能过度积极,尤其是60岁以上男性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To compare the incidence of subsequent prostate cancer diagnosis and death following an initial non-malignant systematic transrectal ultrasonography (TRUS) biopsy with that in an age- and calendar-year matched population over a 20-year period. SUBJECTS AND METHODS: This population-based analysis compared a cohort of all men with initial non-malignant TRUS biopsy in Denmark between 1995 and 2016 (N = 37 231) with the Danish population matched by age and calendar year, obtained from the NORDCAN 9.1 database. Age- and calendar year-corrected standardized prostate cancer incidence (SIR) and prostate cancer-specific mortality ratios (SMRs) were calculated and heterogeneity among age groups was assessed with the Cochran's Q test. RESULTS: The median time to censoring was 11 years, and 4434 men were followed for more than 15 years. The corrected SIR was 5.2 (95% confidence interval [CI] 5.1-5.4) and the corrected SMR was 0.74 (95% CI 0.67-0.81). Estimates differed among age groups (P < 0.001 for both), with a higher SIR and SMR among younger men. CONCLUSION: Men with non-malignant TRUS biopsy have a much higher incidence of prostate cancer but a risk of prostate cancer death below the population average. This underlines that the oncological risk of cancers missed in the initial TRUS biopsy is low. Accordingly, attempts to increase the sensitivity of initial biopsy are unjustified. Moreover, current follow-up after non-malignant biopsy is likely to be overaggressive, particularly in men over the age of 60 years.
引用
- Stroomberg HV, Andersen MCM, Helgstrand JT, et al. Standardized prostate cancer incidence and mortality rates following initial non-malignant biopsy result. BJU Int. 2023. PMID: 36847603. doi:10.1111/bju.15997
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。